Clinical Trial Media Achieves High Diversity in Alzheimer's and Other Trials Using AI

Key Insights

• Clinical Trial Media (CTM) achieved 62% diverse participant randomization in an Alzheimer's Disease trial, where the condition is most prevalent among Black and Hispanic women.
• CTM also attained 32% diverse randomization in a cardiometabolic program and 59% in an immunology trial for Hidradenitis Suppurativa, which disproportionately affects specific populations.
• The company's success stems from using machine learning to target media buying and tailor messaging, effectively reaching and educating diverse populations about clinical trials.

Clinical Trial Media (CTM) has announced significant success in diversifying clinical trial participation through its machine learning-aided recruitment approach. The company reported achieving 62% diverse participant randomization in a trial for Alzheimer’s Disease, a condition with a higher prevalence among Black and Hispanic women. This outcome addresses a long-standing challenge in clinical research: ensuring trial participants reflect the demographics of those most affected by the condition.

Diversity in Cardiometabolic and Immunology Trials

CTM's efforts extend beyond Alzheimer's, with 32% diverse randomization achieved in a cardiometabolic program focused on conditions that disproportionately affect American Indian, Alaskan Native, Black, and Hispanic populations. Additionally, an immunology trial for Hidradenitis Suppurativa (HS), a condition more prevalent among Black women, saw 59% of CTM’s randomizations coming from diverse populations.

Addressing the Diversity Gap

Cara Brant, CEO of Clinical Trial Media, emphasized that interest in clinical trial participation exists across all populations. The primary challenge lies in effectively identifying and educating individuals about available trials and creating accessible participation conditions. CTM's approach combines technology with personalized care to bridge this gap.

Technology and Personalized Care

CTM's StudyMax technology leverages machine learning to hyper-target media buying, enabling effective outreach and education to diverse populations. This includes geo-specific advertising and tailored messaging. The company also maintains a database of over three million potential participants through ExploreClinicalResearch.com, where individuals can learn about trials and express interest in participating.

A dedicated team of skilled nurses ensures potential participants meet trial criteria and remain engaged throughout the study. This human-led approach accounts for individual lifestyle nuances and ensures participants are fully informed about the trial requirements.

StudyMax Technology

Clinical Trial Media has invested years in developing and testing its StudyMax technology, drawing on over two decades of clinical trial recruitment experience. The company continually updates its technology suite to enhance recruitment effectiveness and help sponsors meet their diversity goals.